Infrequent laboratory abnormalities during terbinafine therapy for onychomycosis: A retrospective cohort analysis within an integrated health system

Kurt S Wenk; Xinxie Wu; Michael J Miller

doi:10.1016/j.jaad.2023.08.086

Infrequent laboratory abnormalities during terbinafine therapy for onychomycosis: A retrospective cohort analysis within an integrated health system

J Am Acad Dermatol. 2025 May;92(5):1080-1082. doi: 10.1016/j.jaad.2023.08.086. Epub 2023 Sep 15.

Authors

Kurt S Wenk¹, Xinxie Wu², Michael J Miller³

Affiliations

¹ Department of Dermatology, Mid-Atlantic Permanente Medical Group, Springfield, Virginia. Electronic address: kurt.s.wenk@kp.org.
² Mid-Atlantic Permanente Medical Group, Rockville, Maryland.
³ Mid-Atlantic Permanente Medical Group, Rockville, Maryland; Mid-Atlantic Permanente Research Institute, Rockville, Maryland.

PMID: 37717727
DOI: 10.1016/j.jaad.2023.08.086

No abstract available

Keywords: abnormality; aminotransferase; cohort; drug-induced liver injury; hepatotoxicity; infrequent; laboratory; monitoring; onychomycosis; retrospective; terbinafine.